TELCON RF PHARMACEUTICAL. Inc (200230) Fair Value & Analysis
Healthcare · KR · Market cap 2.6B KRW
Fair value as of: Jul 7, 2026
From 13 valuation models · updated today
Fair value updated Jul 7, 2026 — revised from 7,396 KRW to 402.46 KRW (−94.6%) since Jun 24, 2026. Share price +481.9% over the past month.
Price vs Fair Value (12 months)
12‑month range 360.00 KRW – 3,800 KRW · fair‑value band 388.35 KRW – 415.09 KRW · the 2,095 KRW price screens above the 402.46 KRW fair value. As of Jul 7, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
TELCON RF PHARMACEUTICAL. Inc (200230) currently trades at 2,095 KRW, while our model-based Fair Value estimate is 402.46 KRW — implying the stock looks roughly 80.8% overvalued today. We read business quality at 53/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: medium).
Over the trailing twelve months, TELCON RF PHARMACEUTICAL. Inc generated revenue of 42.9B KRW at a net margin of -19.4%. Revenue declined 2.8% year over year. It earns a return on equity of -10.0%. Net debt stands at 6.2B KRW. Fundamentals as of Jul 7, 2026
Our scenario range runs from 388.35 KRW (bear case) to 415.09 KRW (bull case); at 2,095 KRW, the current price sits above that range. The share trades about 52% below its 52-week high. For context, the median of 10 Healthcare peers we cover trades at -49% fair-value upside — at -81%, 200230 screens richer than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 7, 2026. TTM = trailing twelve months.
About the company
TELCON RF PHARMACEUTICAL. Inc. primarily engages in the development, production, and sale of RF coaxial connectors worldwide. It also provides coaxial couplers, distributors, and arresters, as well as cable assemblies; and pharmaceuticals. The company was formerly known as Telcon Co., Ltd. TELCON RF PHARMACEUTICAL. Inc. was founded in 1999 and is headquartered in Yongin-si, South Korea.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
TELCON RF PHARMACEUTICAL. Inc reported revenue of 43.2B KRW in FY2025 versus 37.8B KRW in FY2021, a compound +3.3%/yr. Reported net income was −11.5B KRW in FY2025.
Is 200230 fairly valued? → Check now
Similar stocks
10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jul 7, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Jiangsu Hengrui Pharmaceuticals Co 1276 | HK$57.85 | HK$29.84 | -48% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,782 | ₹915.92 | -49% |
| Zoetis Inc Z1TS34 | R$24.45 | R$6.33 | -74% |
| Hansoh Pharmaceutical Group 3692 | HK$29.32 | HK$23.94 | -18% |
| Divi's Laboratories Limited DIVISLAB | ₹6,623 | ₹1,461 | -78% |
| Torrent Pharmaceuticals Limited TORNTPHARM | ₹4,464 | ₹1,504 | -66% |
| Cipla Limited CIPLA | ₹1,377 | ₹628.39 | -54% |
| Zydus Lifesciences Limited ZYDUSLIFE | ₹1,089 | ₹841.98 | -23% |
| Dr. Reddy's Laboratories Limited DRREDDY | ₹1,291 | ₹1,053 | -18% |
| PharmaEssentia Corporation 6446 | 934.00 TWD | 365.87 TWD | -61% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is TELCON RF PHARMACEUTICAL. Inc (200230) undervalued?
What is the fair value of 200230?
What is the quality score of 200230?
What is the revenue of TELCON RF PHARMACEUTICAL. Inc (200230)?
What is the net profit margin of 200230?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.